Physician profile
Nikhil Sheth
NPI 1457308843
$304.65
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $43.49 | 2019 | |
| Astellas Pharma US INC | $39.65 | 2019 | |
| Janssen Scientific Affairs, LLC | $36.94 | 2019 | |
| Baxter Healthcare | $29.44 | 2019 | |
| Endo Pharmaceuticals INC. | $25.86 | 2019 | |
| Allergan, INC. | $22.16 | 2019 | |
| Travere Therapeutics, INC. | $20.06 | 2019 | |
| Dendreon Pharmaceuticals LLC | $18.50 | 2019 | |
| Amgen INC. | $17.51 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.22 | 2019 | |
| Pfizer INC. | $17.03 | 2019 | |
| Abbvie INC. | $16.79 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.